When should antiplatelet therapy be restarted in a patient with a subdural hematoma who was previously on dual antiplatelet therapy (aspirin and clopidogrel) after coronary artery stenting?

Timing of Antiplatelet Resumption After Subdural Hematoma in Post-Stenting Patients

In patients with subdural hematoma who were on dual antiplatelet therapy after coronary stenting, restart aspirin as soon as hemostasis is achieved (typically within 1-7 days after imaging confirms stability), and resume clopidogrel after 1-4 weeks based on stent type and thrombotic risk, with mandatory multidisciplinary discussion involving cardiology, neurosurgery, and hematology to balance stent thrombosis risk against rebleeding risk.

Critical Decision Framework

The timing decision hinges on three key factors that must be assessed systematically:

1. Stent Type and Time Since Placement

Drug-eluting stents (DES) carry the highest thrombotic risk, particularly within the first 6-12 months 1, 2. The risk of stent thrombosis is catastrophic—often fatal or resulting in massive MI. For bare-metal stents (BMS), the critical window is shorter at 3-4 weeks 3.

• If DES placed <6 months ago: This represents major thrombotic risk. Aspirin should be restarted within days, clopidogrel within 1-2 weeks maximum 1
• If DES placed >6 months ago: Moderate risk. Can delay clopidogrel restart to 3-4 weeks 1
• If BMS placed >4 weeks ago: Lower risk. More flexibility in timing 3

2. Subdural Hematoma Stability

Obtain repeat CT imaging at 24-48 hours to confirm hematoma stability before any antiplatelet resumption 4. The FDA label explicitly states clopidogrel is contraindicated in active intracranial hemorrhage 4.

• If hematoma is stable/resolving: Proceed with staged antiplatelet resumption
• If hematoma is expanding: Delay all antiplatelets; repeat imaging in 48-72 hours
• If residual hematoma present: Rebleeding risk increases to 41-62% with antiplatelet resumption 5. Consider waiting until complete resolution unless thrombotic risk is prohibitive

3. Surgical vs. Conservative Management

• Post-surgical evacuation: Can restart earlier as hemostasis is achieved surgically 4, 6
• Conservative management: Requires longer observation period before restart

Specific Restart Protocol

Aspirin Resumption (First Agent)

Start aspirin 75-100 mg daily once:

• Repeat CT at 24-48 hours shows stability
• No active bleeding signs
• Typically within 1-7 days post-hemorrhage 1, 7

The 2024 ESC guidelines support aspirin monotherapy as relatively safe even in high-risk scenarios 2. A 2025 randomized trial found continuous aspirin did not increase cSDH recurrence rates 8, though this applies to chronic subdural hematomas specifically.

Clopidogrel Resumption (Second Agent)

The French Task Force recommends a 5-day window for clopidogrel discontinuation in high-risk stent patients, with resumption as soon as possible after hemostasis 1. However, this must be balanced against subdural rebleeding risk.

Timing algorithm:

• High thrombotic risk (DES <6 months, history of stent thrombosis, multiple stents): Resume clopidogrel at 7-14 days post-hemorrhage if imaging stable 1, 6
• Moderate thrombotic risk (DES >6 months, BMS >4 weeks): Resume at 2-4 weeks 6, 9
• Consider loading dose of 300-600 mg when restarting to rapidly restore antiplatelet effect 1

Critical Warnings and Pitfalls

The Stent Thrombosis Catastrophe

Premature discontinuation of dual antiplatelet therapy after stenting causes stent thrombosis with mortality rates of 20-45% 1. The FDA label explicitly warns that discontinuation increases cardiovascular event risk 4. One study found 5.8-16% thrombotic event rates when anticoagulation/antiplatelet therapy was delayed 6.

The Rebleeding Risk

Anticoagulants (not antiplatelets) are the primary driver of subdural rebleeding. Studies show anticoagulants increase rebleeding odds ratio 1.75-2.7, while antiplatelets were NOT associated with increased rebleeding 9. However, if residual hematoma is present, rebleeding risk climbs to 41-62% 5.

The Inappropriate Prescribing Problem

A 2025 study found 31% of patients with subdural hematomas were on inappropriate antithrombotic therapy before their hemorrhage 10. Primary/secondary stroke prevention and cardiac stents were the most common inappropriate indications. This highlights the need to verify the indication is truly appropriate before resuming therapy.

Mandatory Multidisciplinary Discussion

The French Task Force explicitly requires documented multidisciplinary team meetings for these decisions 1. This must include:

• Cardiologist: To assess stent thrombosis risk and whether patient can tolerate aspirin monotherapy temporarily
• Neurosurgeon: To assess hemorrhage stability and rebleeding risk
• Hematologist/Thrombosis specialist: To optimize timing and dosing

Document the risk-benefit analysis and agreed-upon plan in the medical record 1.

Bridging Strategy Considerations

For highest-risk patients (recent DES, multiple stents, prior stent thrombosis), some experts suggest:

• Maintain aspirin throughout if possible 1
• Hold clopidogrel for minimum necessary time (5-10 days maximum) 1
• Do NOT use heparin bridging—it substantially increases bleeding risk without proven benefit in this context 1

Post-Discharge Monitoring

Resume dual antiplatelet therapy for the remaining duration required by stent type 2:

• BMS: Total 1-3 months DAPT (so if 2 weeks were missed, continue for remaining time)
• DES: Total 6-12 months DAPT minimum 2
• After DAPT period, continue aspirin monotherapy indefinitely 2

Counsel patients that the dual therapy is temporary and they will transition to monotherapy after the critical stent period 11.